The US Food and Drug Administration (FDA) has provided Emergency Use Authorisation (EUA) to PerkinElmer for its New Coronavirus RT-PCR test. Laboratories certified under Clinical Laboratory Improvement Amendments (CLIA) can immediately begin using the test to detect the virus that causes Covid-19.
Perkin Elmer’s RT-PCR test is an in vitro diagnostic that is available in over 30 countries worldwide.
PerkinElmer CEO Prahlad Singh said: “Despite the challenging environment, our employees have demonstrated unwavering commitment over the past two months to combat this global pandemic. The breadth of PerkinElmer’s total workflow solution puts us in a unique position to rapidly address the needs of our clinical diagnostics customers.”